1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Competitor Analysis ErbB / Her Receptor Antagonists

Competitor Analysis ErbB / Her Receptor Antagonists

  • July 2013
  • -
  • La Merie Publishing
  • -
  • 168 pages

Competitor Analysis ErbB / Her Receptor Antagonists

Product description

The present Competitive Intelligence Report about antagonists of the ErbB/Her receptor pathway provides a competitor evaluation in the field of ErbB1 (EGF-R), ErbB2 (Her), ErbB3 (Her) and ErbB4 (Her4) receptor targeting molecules for treatment of cancer as of July 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Targeted treatment of EGF-R and Her2-positive cancers with target specific antibodies has become an example of successful personalized medicine. The commercial success of small molecule ErbB/Her receptor tyrosine kinase inhibitors and EGF-R and Her2 targeted antibody  therapy has spurred the discovery and development of efficacy enhanced versions as well as of ErbB dual or multi-target therapies.
The report includes a compilation of current active projects in research and development of molecules targeting the receptors of the ErbB/Her family. In addition the report lists company-specific R&D pipelines of ErbB/Her receptor targeting molecular entities.

Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis ErbB / Her Receptor Antagonists
Competitor Analysis ErbB / Her Receptor Antagonists
Table of Contents

• Sales of Small Molecules Inhibitors of the ErbB/Her Receptor Family
• Sales of Antibodies Targeting ErbB/Her Receptors

1) Small Molecules Targeting the ErbB/Her Receptor Family

a) Selective EGF-R Tyrosine Kinase (TK) Inhibitors

- Tarceva Pipeline

- Iressa Pipeline

- Pipeline of Other EGF-R Selective TK Inhibitors

b) Selective Her2 (ErbB2) TK Inhibitors

c) Dual EGF-R (ErbB1) and Her2 (ErbB2) TK Inhibitors

- Tykerb  Pipeline

- Pipeline of Other Dual EGF-R (ErbB1) and Her2 (ErbB2) TK Inhibitors

d) Pan-Her (EGF-R, Her2 and Her4) / pan-Erb (ErbB1, ErbB2, ErbB4) TK Inhibitors

- Gilotrif Pipeline

- Neratinib Pipeline

- Dacomitinb Pipeline

- Poziotinib Pipeline

- Pipeline of Other Pan-Her Tk Inhibitors

e) Multi-Target TK Inhibitors incl. EGF-R (ErbB1) Inhibition

f) Multi-Target TK Inhibitors incl. EGF-R (ErbB1) and Her2 (ErbB2) Inhibition
2) Biologics (Cells, Proteins, RNA) Targeting the ErbB/Her Receptor Family
3) Vaccines Targeting the ErbB/Her Receptor Family

a) EGF-R (ErbB1) Vaccines

b) Her2 (ErbB2) Vaccines

c) Her3 (ErbB3) Vaccines
4) Antibodies Targeting the ErbB/Her Receptor Family

a) Selective EGF-R (ErbB1) Antibodies

- Erbitux Pipeline

- Vectibix Pipeline

- Nimotuzumab Pipeline

- Pipeline of Other Selective EGF-R (ErbB1) Antibodies

- Biosimilar Cetuximab Pipeline

- Biosimilar Panitumumab Pipeline


b) Selective Her2 (ErbB2) Antibodies

- Herceptin Pipeline

- Perjeta Pipeline

- Kadcyla Pipeline

- Pipeline of Other Selective Her2 (ErbB2) Antibodies

- Biosimilar Trastuzumab Pipeline

c) Selective Her3 (ErbB3) Antibodies

d) Dual and Pan ErbB / Her Antibodies

e) Dual Target Antibodies incl. ErbB/Her Receptor Antagonism
5) Corporate ErbB/Her Receptor Antagonist Randamp;D Pipelines

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Therapy Market in Denmark - Forecast

  • December 2016
    12 pages
  • Therapy  

  • Denmark  

View report >

Therapy Market in New Zealand - Forecast

  • December 2016
    71 pages
  • Therapy  

  • New Zealand  

View report >

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.